menu
    • menu
    [{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Abicipar Pegol","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Abicipar Pegol","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Molecular Partners \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ AbbVie"}]

    Find Clinical Drug Pipeline Developments & Deals for Abicipar Pegol

    Menu

    Abicipar Pegol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allergan Aesthetics

                            U.S.A
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abicipar Pegol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol

                            Details : Allergan, an AbbVie has informed Molecular Partners of their intent to withdraw application filings with both the EMA and the Japanese Regulatory Agency (PMDA) for abicipar pegol, a novel DARPin therapeutic for patients with neovascular (wet) age-related...

                            Brand Name : Abicipar

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 20, 2020

                            Lead Product(s) : Abicipar Pegol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Molecular Partners

                            Switzerland arrow
                            PackExpo
                            Not Confirmed

                            Molecular Partners

                            Switzerland arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abicipar Pegol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Molecular Partners to Regain Global Rights to Abicipar

                            Details : Abicipar is a long-acting anti-VEGF DARPin® molecule which was invented by Molecular Partners and initially licensed to Allergan in 2011.

                            Brand Name : AGN-150998

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 09, 2021

                            Lead Product(s) : Abicipar Pegol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth